Claim being evaluated

Improves metabolic health

A claim to investigate, not an established benefit. Each outcome below is assessed separately.

What the evidence suggests

Insulin sensitivity, glucose control or body weight: There are no published human results on whether MOTS-c improves insulin sensitivity, blood sugar control or body weight in people with obesity, insulin resistance or diabetes. One placebo-controlled trial is underway but has not reported findings. The evidence is insufficient to say whether MOTS-c helps, and this is not evidence that it does not work.

What remains unknown: Whether MOTS-c changes insulin sensitivity, glucose control or body weight in humans. Its effects in people with type 2 diabetes. Effects on patient-important outcomes and longer-term outcomes. Its safety and adverse effects. Trial design details such as randomization and blinding.

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated by rule (no eligible human study was found), not reviewed by a person.

Certainty by outcome

Insulin sensitivity, glucose control or body weight

Insufficient information to assess

Surrogate outcome · 1 study · 0 participants

Not enough evidence to tell

There are no published human results on whether MOTS-c improves insulin sensitivity, blood sugar control or body weight in people with obesity, insulin resistance or diabetes. One placebo-controlled trial is underway but has not reported findings. The evidence is insufficient to say whether MOTS-c helps, and this is not evidence that it does not work.

What the research measured: One registered placebo-controlled trial of MOTS-c in adults with prediabetes and overweight/obesity targets insulin sensitivity. It is recruiting and has no reported results, so no effect on insulin sensitivity, glucose control or body weight has been measured.

What remains unknown: Whether MOTS-c changes insulin sensitivity, glucose control or body weight in humans. Its effects in people with type 2 diabetes. Effects on patient-important outcomes and longer-term outcomes. Its safety and adverse effects. Trial design details such as randomization and blinding.

Reviewers’ note: The only eligible study is a registered, recruiting trial with no posted results. Without any outcome data, no GRADE certainty rating can be assigned.

How the certainty was judged
GRADE domain judgments
DomainJudgmentWhy
Starting level—
Risk of bias—Randomization, allocation concealment and blinding are not described in the registry record, and outcomes are not prespecified in the stored fields; no results exist to appraise.
Inconsistency—Only one registered study is eligible, and it has no reported results, so consistency cannot be assessed.
Indirectness—Population (prediabetes, overweight/obesity, insulin resistance), MOTS-c versus placebo and insulin sensitivity outcome match the question.
Imprecision—No outcome data or effect estimates have been reported; the trial is still recruiting with an estimated planned enrollment of 120.
Publication bias—A registered trial that is still recruiting has no posted results, and no published data exist for it among the included studies.

Included studies

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · GRADE (handbook, 2013) · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

The questions and the studies screened

Population, intervention, comparator and outcome (PICO), and why each study was or wasn’t eligible.

Population: Adults with obesity, insulin resistance or type 2 diabetes · Intervention: MOTS-c · Comparator: Placebo or none · Outcome: Insulin sensitivity, glucose control or body weight

  • PLS-00037: not eligible (not primary study)
  • PLS-00038: not eligible (not primary study)
  • PLS-00039: not eligible (not primary study)
  • PLS-00040: not eligible (not primary study)
  • PLS-00041: not eligible (not primary study)
  • PLS-00042: not eligible (not primary study)
  • PLS-00043: not eligible (not primary study)
  • PLS-00044: not eligible (not primary study)
  • PLS-00045: not eligible (not primary study)
  • PLS-00046: not eligible (not primary study)
  • PLS-00047: not eligible (not primary study)
  • PLS-00048: not eligible (not primary study)
  • PLS-00049: not eligible (not primary study)
  • PLS-00050: not eligible (not primary study)
  • PLS-00051: not eligible (not primary study)
  • PLS-00052: not eligible (not primary study)
  • PLS-00053: not eligible (not primary study)
  • PLS-00054: not eligible (not primary study)
  • PLS-00055: not eligible (not primary study)
  • PLS-00056: not eligible (not primary study)
  • PLS-00057: not eligible (not primary study)
  • PLS-00058: not eligible (not primary study)
  • PLS-00059: not eligible (not primary study)
  • PLS-00060: not eligible (not primary study)
  • PLS-00061: not eligible (not primary study)
  • PLS-00062: not eligible (not primary study)
  • PLS-00063: not eligible (not primary study)
  • PLS-00064: not eligible (not primary study)
  • PLS-00065: not eligible (not primary study)
  • PLS-00066: not eligible (not primary study)
  • PLS-00067: not eligible (not primary study)
  • PLS-00068: not eligible (not primary study)
  • PLS-00069: not eligible (not primary study)
  • PLS-00070: not eligible (not primary study)
  • PLS-00071: not eligible (not primary study)
  • PLS-00072: not eligible (not primary study)
  • PLS-00073: not eligible (not primary study)
  • PLS-00074: not eligible (not primary study)
  • PLS-00075: not eligible (not primary study)
  • PLS-00076: not eligible (not primary study)
  • PLS-00077: not eligible (not primary study)
  • PLS-00078: not eligible (not primary study)
  • PLS-00079: not eligible (not primary study)
  • PLS-00080: not eligible (not primary study)
  • PLS-00081: not eligible (not primary study)
  • PLS-00082: not eligible (not primary study)
  • PLS-00083: not eligible (not primary study)
  • PLS-00084: not eligible (not primary study)
  • PLS-00085: not eligible (not primary study)
  • PLS-00086: not eligible (not primary study)
  • PLS-00087: not eligible (not primary study)
  • PLS-00088: not eligible (not primary study)
  • PLS-00089: not eligible (not primary study)
  • PLS-00090: not eligible (not primary study)
  • PLS-00091: not eligible (not primary study)
  • PLS-00092: not eligible (not primary study)
  • PLS-00093: not eligible (not primary study)
  • PLS-00094: not eligible (not primary study)
  • PLS-00095: not eligible (not primary study)
  • PLS-00096: not eligible (not primary study)
  • PLS-00207: not eligible (not primary study)
  • PLS-00249: eligible · direct evidence: Adults with prediabetes and overweight/obesity receive MOTS-c versus placebo, targeting insulin sensitivity. This matches the claim's PICO, but no results are reported yet.

Version history

  • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated by rule (no eligible human study was found), not reviewed by a person.

How claims are assessed

These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).